Panel Discussion: Beyond TfR1: Evaluating Next‑Generation BBB Receptors for Systemic Biologic Delivery to the Brain

• Which alternative BBB receptors (e.g. CD98hc, Ca4, ALPL, glycan and others) show the most promise beyond TfR1 for achieving sufficient brain uptake without compromising safety or peripheral PK?
• How can we optimize receptor affinity, valency, and trafficking profiles to balance efficient transcytosis with minimal lysosomal degradation or target-mediated clearance, as it pertains to payloads?
• Improving brain specific and cell specific targeting
• How should developers prioritize receptor selection based on modality (e.g. antibodies, enzymes, oligonucleotides) and indication-specific needs for brain distribution and cellular targeting?

Speakers:

Peter Horanyi

Senior Principal Scientist

UCB

James Gorman

Principal Investigator, Brain Targeting Program

WYSS Institute, Harvard Medical School

Sophia Shi

Principal Investigator

Rowland Institute, Harvard University

Urs Langen

Lab Head & Research Project Leader

Roche